I was just talking about this so I’ll share it h
Post# of 155444
(Total Views: 977)
Posted On: 03/08/2025 10:27:42 AM
Re: skipper1072 #150864
I was just talking about this so I’ll share it here. These trials are all done. I listed the pooled data that Cytodyn put together that will be used for the upcoming data on mTNBC in May.
A small group lived beyond 36 months as per the last PR and are now cancer free. I hope that this data, even though small, will give us the green light to apply for BTD again. Depending on the survival numbers, this could be a big deal.
Here’s the breakdown down of all 28 treated for mTNBC. Figured it would be a good reference since it’s been awhile since this was discussed. The data and publications should be available mid May.
• All patients were listed as mTNBC
• n=16 were from Compassionate Use
• n=10 were from mTNBC trial
. n=2 were from Basket trial
• Patients received 21 dose of Leronlimab (range 1 - 33 doses)
• Doses ranged from 350mg - 700mg
• 4 patients had dose escalation per study protocol
• Average age was 52 (range 33 - 75)
This data was as reported by August 15, 2021.
I can’t recall how many survivors were left on the last update. I thought it was shared at some point back in 2021. The CTCs significantly decreased with leronlimab. The potential here is pretty incredible the more you dig into it.
A small group lived beyond 36 months as per the last PR and are now cancer free. I hope that this data, even though small, will give us the green light to apply for BTD again. Depending on the survival numbers, this could be a big deal.
Here’s the breakdown down of all 28 treated for mTNBC. Figured it would be a good reference since it’s been awhile since this was discussed. The data and publications should be available mid May.
• All patients were listed as mTNBC
• n=16 were from Compassionate Use
• n=10 were from mTNBC trial
. n=2 were from Basket trial
• Patients received 21 dose of Leronlimab (range 1 - 33 doses)
• Doses ranged from 350mg - 700mg
• 4 patients had dose escalation per study protocol
• Average age was 52 (range 33 - 75)
This data was as reported by August 15, 2021.
I can’t recall how many survivors were left on the last update. I thought it was shared at some point back in 2021. The CTCs significantly decreased with leronlimab. The potential here is pretty incredible the more you dig into it.
(20)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
Federal Whistleblower / Special Operations Tactical Unit
USAF: Phoenix Raven #2143
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
Founder & CEO of FireGate Bioscience
USPTO: Lead Inventor of the HIV Cure & AI Federal Oversight Program
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com